Patients with clear cell carcinoma were younger than those with high-grade serous carcinoma, with reported ages of 51 versus 58 years, and they had lower CA-125 levels. They also received frontline PARP inhibitors less frequently: 4.8% compared with 24% among patients with high-grade serous disease, a difference with a p value of 0.007. The objective response rate was numerically higher among bevacizumab recipients than among patients who did not receive the drug, at 90% versus 78%, but this comparison did not meet the conventional statistical threshold (p = 0.078).

Bevacizumab use was also associated with a different recurrence pattern. The abstract reported disseminated peritoneal recurrence in 31% of bevacizumab recipients versus 49% without bevacizumab, while pelvic or focal recurrence occurred in 15% and 2.2%, respectively; the overall comparison between recurrence patterns had a p value of 0.025. Kaplan–Meier analyses found significantly better overall survival (p = 0.0012) and progression-free survival (p = 0.01) with bevacizumab across the full cohort. The overall-survival association was particularly pronounced in the high-grade serous subgroup (p = 0.0061).

In multivariable analysis, clear cell histology independently predicted worse overall survival, with a hazard ratio of 3.03 (95% confidence interval, 1.71–5.34; p < 0.001), and worse progression-free survival, with a hazard ratio of 1.81 (95% CI, 1.10–3.00; p = 0.02). Frontline bevacizumab was independently associated with longer overall survival, with a hazard ratio of 0.52 (95% CI, 0.30–0.90; p = 0.019). The survival association in the clear cell subgroup did not reach statistical significance, although its direction was consistent with that in high-grade serous carcinoma, and no significant interaction by histology was detected (p = 0.505). The authors noted that the retrospective design and limited subgroup sizes require validation in prospective studies; the supplied evidence is an abstract from an early-access version subject to further edits, not a full assessment of the article.

Subject of Research: Associations between frontline bevacizumab, survival, and recurrence patterns in advanced ovarian cancer by histology

Article Title: Frontline bevacizumab in ovarian clear cell versus high-grade serous ovarian cancer: survival outcomes and recurrence patterns in a real-world cohort

Article References: Gao, Y.-T., Chang, C. Y.-Y., Chang, W.-C., Hung, Y.-C., Lin, W.-C., Sung, Y.-W., & Yeh, L.-S. (2026). Frontline bevacizumab in ovarian clear cell versus high-grade serous ovarian cancer: survival outcomes and recurrence patterns in a real-world cohort. BMC Cancer. https://doi.org/10.1186/s12885-026-17030-x

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17030-x

Keywords: ovarian cancer, bevacizumab, clear cell carcinoma, high-grade serous carcinoma, overall survival, progression-free survival, recurrence patterns, retrospective cohort, observational study, Frontline, ovarian, clear

The factorial architecture is the trial’s defining technical feature. Rather than comparing a single combined treatment against a control, the investigators treat acupuncture and moxibustion as two independent randomized factors, each present or absent. Every participant receives standard oral estradiol/dydrogesterone therapy, marketed as Femoston, following a sequential 28-day regimen: one milligram of estradiol daily for the first 14 days, then one milligram of estradiol plus 10 milligrams of dydrogesterone daily for the following 14 days, providing both hormone replacement and endometrial protection. On top of this common hormonal background, women are assigned in a 1:1:1:1 ratio to Femoston alone, acupuncture plus Femoston, moxibustion plus Femoston, or combined acupuncture and moxibustion plus Femoston, with 36 participants in each group.

This design allows statisticians to estimate the main effect of acupuncture by pooling the two groups that receive it, 72 participants, against the 72 who do not, and to do the same for moxibustion. The acupuncture × moxibustion interaction, whether the two modalities amplify or interfere with one another, will also be estimated but is explicitly exploratory, because the trial was not powered specifically for that question. The investigators argue that this structure resolves an ambiguity that plagues conventional three-arm comparisons: if a combined treatment outperforms a control, it is often unclear whether the benefit arises from one component, the other, or their synergy. The factorial design disentangles those possibilities within a single trial.

The primary outcome is the change from baseline to week 12 in antral follicle count, or AFC, the total number of 2 to 9 millimeter antral follicles visible in both ovaries on transvaginal ultrasound. AFC provides a direct ultrasound-based estimate of the recruitable follicle pool and is a clinically recognized marker of ovarian reserve. The 12-week window was chosen on empirical grounds: a prior randomized study in women with POI reported measurable increases in both AFC and anti-Müllerian hormone after a comparable three-month estradiol/dydrogesterone regimen with or without adjunct acupuncture, and a recent 12-week sham-controlled trial in women with diminished ovarian reserve found that acupuncture three times weekly produced significantly greater AFC improvement than sham, although the between-group AMH difference was not statistically significant. Importantly, the protocol cautions that a biomarker change at 12 weeks should not be interpreted as restoration of the primordial follicle pool or of fertility.

Secondary outcomes span the multidimensional clinical burden of POI. Serum anti-Müllerian hormone will be measured in a central laboratory using the Roche Elecsys AMH assay on a cobas e 602 electrochemiluminescence platform, with fasting blood samples processed within two hours, centrifuged, aliquoted, stored at minus 80 degrees Celsius, and transported on dry ice from the three recruitment centers to minimize inter-laboratory variability. Follicle-stimulating hormone, luteinizing hormone, and estradiol will be measured by chemiluminescent immunoassay. Transvaginal color Doppler ultrasound will capture ovarian hemodynamic parameters, including peak systolic velocity, resistance index, and pulsatility index. Patient-reported measures include the modified Kupperman Scale for hypoestrogenic symptoms, the Self-Rating Anxiety Scale for psychological distress, Traditional Chinese Medicine syndrome scores, and menstrual status, all assessed at baseline and week 12.

Clinical pregnancy, defined as an intrauterine gestational sac with fetal cardiac activity confirmed by ultrasound, will be analyzed as an exploratory reproductive outcome recorded during treatment and at follow-up visits at weeks 24 and 48. The trial was not powered for pregnancy endpoints, and the investigators emphasize that conception during follow-up may be strongly influenced by subsequent ovulation induction, in vitro fertilization and embryo transfer, or other assisted reproductive technology. Post-randomization summaries of spontaneous conceptions versus conceptions following ART will be regarded as exploratory rather than randomized causal comparisons. Participants who become pregnant will discontinue acupuncture and moxibustion immediately and transfer to pregnancy follow-up.

The intervention protocol is standardized in unusual technical detail. The acupuncture prescription comprises two alternating treatment sets: set A, performed in the supine position, includes abdominal points CV12, CV6, CV4, bilateral ST25, ST29, EX-CA1, and leg points ST36, SP6, and LR3; set B, performed prone, includes bilateral BL23, BL32, and KI3. Needles of 0.25 by 40 millimeters and 0.30 by 75 millimeters are inserted to prespecified depths, with BL32 advanced obliquely toward the second posterior sacral foramen to 60 to 75 millimeters. Gentle lifting, thrusting, and twirling elicit Deqi, the characteristic sensation of soreness, numbness, distension, or heaviness, and needles are retained for 30 minutes. The moxibustion arm applies self-adhesive moxa column patches, each burning roughly 10 minutes, to the identical acupoints without needle insertion, three columns per session for approximately 30 minutes. In the combined group, moxibustion is applied during needle retention after Deqi is achieved. Both external therapies are delivered three times weekly for 12 weeks, totaling 36 sessions.

Because acupuncture and moxibustion are physical interventions, participants and practitioners cannot be blinded, so the trial adopts an assessor-blinded design. Recruitment and screening personnel are separated from treatment practitioners, who play no role in outcome assessment. Outcome assessors, ultrasound physicians, laboratory technicians, data-entry staff, and statisticians remain blinded to allocation throughout. To minimize measurement variability, all baseline and week-12 AFC examinations, regardless of recruitment center, will be performed centrally in the ultrasound department of the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine using a GE HealthCare LOGIQ Fortis system with an RIC5-9-D transvaginal volume probe, and the same blinded physician will examine the same participant whenever feasible. Adverse events, including vasovagal reactions, hematomas, burns, and hormone-related symptoms such as breast tenderness and abnormal bleeding, will be recorded with a four-level severity grading scheme, and serious events reported to the ethics committee within 24 hours.

The sample size was planned from prior literature in which post-treatment AFC was 3.97 plus or minus 1.15 in the Femoston-only group and 5.14 plus or minus 1.33 in the acupuncture plus Femoston group, a between-group difference of 1.17 corresponding to Cohen’s d of approximately 0.94. G*Power calculations with 90 percent power and a two-sided alpha of 0.05 indicated 26 participants per group, increased to 36 per group to allow for roughly 20 percent dropout, for a total of 144. Within the factorial framework, each factor level includes up to 72 participants, yielding greater than 99 percent power to detect a main effect of that magnitude, with a minimum detectable standardized effect of approximately 0.54 at 90 percent power. The investigators stress that the planning benchmark derived from an acupuncture comparison does not imply the true moxibustion effect equals d of 0.94.

The trial’s eligibility criteria deliberately define a selected subgroup: women aged 22 to 40 with reproductive needs, basal FSH between 25 and 40 U/L confirmed on two occasions at least four weeks apart, and recruitment during the pretreatment phase before assisted reproduction. The investigators acknowledge that these criteria limit generalizability to adolescents, women with more advanced ovarian failure, those without fertility intentions, or patients with substantial comorbidity. The absence of sham controls means subjective outcomes such as anxiety and TCM syndrome scores may reflect treatment expectations and practitioner attention as well as specific physiological effects, although more objective biomarkers like AFC and AMH are less directly susceptible to such contextual influences. Registered with the International Traditional Medicine Clinical Trial Registry under identifier ITMCTR2025002408 and approved by the ethics committee of the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, the trial may clarify whether either modality is associated with changes in ovarian reserve markers when added to standard hormone therapy, and may generate preliminary evidence on their potential interaction, providing a methodological basis for future larger trials designed around definitive reproductive outcomes such as live birth.

Subject of Research: Adjunctive effects of acupuncture and moxibustion in women with premature ovarian insufficiency receiving hormone replacement therapy: protocol for a multicenter, assessor-blinded, 2 × 2 factorial randomized controlled trial

Article Title: Adjunctive effects of acupuncture and moxibustion in women with premature ovarian insufficiency receiving hormone replacement therapy: protocol for a multicenter, assessor-blinded, 2 × 2 factorial randomized controlled trial

Article References: Lu, C., Ye, T., Cui, J., & Chen, B. (2026). Adjunctive effects of acupuncture and moxibustion in women with premature ovarian insufficiency receiving hormone replacement therapy: protocol for a multicenter, assessor-blinded, 2 × 2 factorial randomized controlled trial. Frontiers in Endocrinology, 17, Article 1952726. https://doi.org/10.3389/fendo.2026.1952726

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1952726

Keywords: acupuncture, moxibustion, premature ovarian insufficiency, hormone replacement therapy, factorial randomized controlled trial, reproductive medicine, Adjunctive, effects, women, premature, ovarian, insufficiency

Progestin-primed ovarian stimulation has become an established alternative to antagonist protocols, offering comparable suppression at lower cost and with convenient oral administration. Yet a fundamental question has remained unanswered: when exactly should the progestin start? Most clinics use a fixed regimen, beginning medroxyprogesterone acetate on day two or three of the menstrual cycle, before stimulation drugs begin. A flexible approach would instead delay the progestin until follicles reach a certain size or estradiol crosses a threshold, potentially reducing the total progestin exposure each patient receives. The idea is appealing, but comparative evidence between the two approaches has been scarce, particularly for women whose ovarian reserves are less than ideal.

A team of researchers at Khon Kaen University in Thailand has now provided the first randomized controlled trial data addressing this question in a specific and clinically important population. Their study, published in the Journal of Ovarian Research, enrolled 98 infertile women belonging to POSEIDON groups 1 and 2, a classification system that identifies women with normal or suboptimal ovarian reserve who have previously experienced an unexpected poor response to stimulation. These patients represent a challenging middle ground in fertility medicine: their ovaries are not depleted, but they have a documented history of responding less well than expected to gonadotropin drugs. All participants were undergoing intracytoplasmic sperm injection, a technique in which a single sperm is injected directly into each mature egg.

Participants were randomly assigned in equal numbers to one of two protocols. In the flexible group, medroxyprogesterone acetate was initiated only when follicular size or estradiol levels met predefined criteria, allowing clinicians to individualize the timing based on each patient’s response. In the fixed group, the progestin began on day two or three of the cycle, before any stimulation drugs were given. The researchers designed the study as a non-inferiority trial, meaning their goal was not to prove that the flexible approach was better, but to determine whether it was at least as effective as the fixed regimen at preventing a premature luteinizing hormone surge on the day of the final maturation trigger.

The results were striking in their simplicity. A premature luteinizing hormone surge occurred in just one of 49 women in the flexible group, an incidence of 2.04 percent, while none of the 49 women in the fixed group experienced one. The absolute difference between the groups was 2.04 percent, with a 95 percent confidence interval ranging from negative 1.92 to 6.00 percent, and the p-value exceeded 0.999. According to the predefined non-inferiority margin, this outcome demonstrated that the flexible protocol was indeed non-inferior to the fixed approach. Notably, premature ovulation was not observed in either group, confirming that both strategies successfully protected the cycles from the most damaging consequence of an early surge.

Beyond the primary outcome, the researchers examined a battery of secondary measures that reflect the quality of the stimulation and the potential for successful fertilization. The number of oocytes retrieved, the number of mature metaphase II oocytes, the fertilization rate, the cleavage rate, and the blastocyst rate were all statistically comparable between the two groups. Even the proportion of good-quality blastocysts, the embryos most likely to lead to a successful pregnancy, showed no meaningful difference. One patient in each group developed moderate to severe ovarian hyperstimulation syndrome, a potentially serious complication of stimulation, with an identical incidence of 2.04 percent in both arms.

Perhaps the most clinically meaningful finding was the difference in progestin exposure itself. The duration of medroxyprogesterone acetate administration was significantly shorter in the flexible group, which is exactly what the flexible approach was designed to achieve. Reducing the total progestin exposure matters for several reasons. Progestins can influence the endometrium, the uterine lining that must be receptive for embryo implantation in subsequent frozen embryo transfer cycles. Shorter exposure may also reduce side effects and align better with a growing movement in reproductive medicine toward patient-centered, individualized treatment rather than one-size-fits-all protocols.

The significance of this trial extends beyond the immediate question of progestin timing. The POSEIDON classification system, which stands for Patient-Oriented Strategies Encompassing Individualized Oocyte Number, was developed to help clinicians tailor stimulation strategies to specific patient profiles. Women in groups 1 and 2 have normal or suboptimal ovarian reserve but a history of unexpected poor response, making them a particularly vulnerable population for cycle failure. Demonstrating that a flexible progestin-primed approach works as well as a fixed one in this group gives fertility specialists a new tool for individualizing care without compromising outcomes.

The trial was registered with the Thai Clinical Trials Registry and received ethics approval from the Khon Kaen University Ethics Committee for Human Research. The researchers analyzed their data using an intention-to-treat approach, which includes all randomized participants regardless of whether they completed the protocol exactly as assigned. This method is considered the gold standard for randomized controlled trials because it preserves the benefits of randomization and avoids bias that can arise from excluding patients after assignment. The study was supported by the Research and Development Fund of the Faculty of Medicine at Khon Kaen University.

For patients and clinicians alike, the message from this trial is one of reassurance and expanded choice. Women with suboptimal to normal ovarian reserve who have previously responded poorly to stimulation can now be offered a flexible progestin-primed protocol with confidence that it will suppress the premature luteinizing hormone surge just as effectively as the traditional fixed regimen. The shorter progestin exposure, combined with equivalent oocyte yield, fertilization rates, and embryo development, suggests that individualized timing is not only safe but potentially preferable. As fertility medicine continues to evolve toward more personalized approaches, this randomized controlled trial provides solid evidence that flexibility in progestin priming is a viable and patient-centered strategy.

Subject of Research: Reproductive Medicine

Article Title: Flexible versus fixed progestin-primed ovarian stimulation for preventing premature luteinizing hormone surge in POSEIDON groups 1–2: a non-inferiority randomized controlled trial

Article References: Tangterdchanakit, R., Sothornwit, J., Aupongkaroon, P., Pongsritasana, T., Sukkasame, S., & Salang, L. (2026). Flexible versus fixed progestin-primed ovarian stimulation for preventing premature luteinizing hormone surge in POSEIDON groups 1–2: a non-inferiority randomized controlled trial. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02312-6

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02312-6

Keywords: Flexible, versus, fixed, progestin-primed, ovarian, stimulation, preventing, premature, luteinizing, hormone, surge, POSEIDON

The research team focused on the selective CXCR4 antagonist USL311, a molecule designed to interfere with the receptor that binds the chemokine CXCL12. The CXCL12/CXCR4 axis is a well-established chemokine network that guides tumor cell migration, survival, and proliferation, and it has been implicated in the homing of ovarian cancer cells to metastatic sites such as the peritoneum. Because of its central role, CXCR4 has become a key therapeutic target across multiple cancer types, with antagonists like plerixafor already approved for other clinical uses. However, the biological consequences of prolonged high-dose inhibition had remained poorly characterized, particularly in heterogeneous ovarian cancer models.

To address this gap, the investigators treated two ovarian cancer cell lines, ES2 and HAY, with three concentrations of USL311: 50, 75, and 100 micromolar, over a 72-hour period. These cell lines represent distinct ovarian cancer subtypes, allowing the researchers to probe whether the molecular response to CXCR4 blockade is uniform across the disease or lineage-specific. The team then deployed a battery of assays including Western blot analysis to quantify protein expression and signaling cascades, immunofluorescence to visualize subcellular protein localization, cytotoxicity assays to measure cell death, and wound-healing assays to assess migratory capacity.

The results revealed a highly discrete, lineage-specific molecular response. In ES2 cells, the researchers observed a prominent biphasic pattern. At 50 micromolar, USL311 significantly suppressed both CXCR4 and Cyclin D1 expression, the latter being a critical regulator of cell-cycle progression from G1 to S phase. This moderate inhibition also dampened oncogenic signaling, suggesting that moderate CXCR4 blockade can effectively push these cells away from a proliferative state. However, when the concentration was raised to 75 or 100 micromolar, the ES2 cells mounted a paradoxical rebound in CXCR4 and Cyclin D1 expression, even though phosphorylated AKT, a key survival kinase, was suppressed and cytotoxicity was markedly increased.

The mechanistic driver of this rebound in ES2 cells was identified as HIF1α, the hypoxia-inducible factor 1-alpha. HIF1α is a transcription factor that becomes stabilized under low-oxygen conditions and orchestrates an adaptive stress program that allows cells to survive hostile microenvironments. The study found that the paradoxical rebound expression of CXCR4 and Cyclin D1 at higher USL311 concentrations was dependent on this HIF1α-mediated adaptive stress mechanism. In other words, the cancer cells interpreted the excessive pharmacologic pressure as a form of stress and responded by reactivating the very oncogenic program that the drug was designed to suppress, albeit through a stress-induced rather than a canonical growth-factor-driven pathway.

Conversely, HAY cells bypassed the HIF1α-dependent cascade entirely. Under identical conditions of high-dose USL311 exposure, HAY cells initiated a compensatory escape network marked by a structural rebound in phosphorylated AKT activation. This is significant because AKT, or Protein Kinase B, is a central node in the PI3K/AKT/mTOR pathway that promotes cell survival, proliferation, and metabolism. The rebound in p-AKT suggests that HAY cells possess an intrinsic ability to restore survival signaling even when the upstream CXCR4 receptor is pharmacologically silenced. Moreover, the researchers documented significant upregulation of MMP2 and MMP9, two matrix metalloproteinases that degrade the extracellular matrix and facilitate invasion and metastasis, in these cells under the same high-dose conditions.

The upregulation of MMP2 and MMP9 in HAY cells is particularly concerning from a therapeutic standpoint. These enzymes are well-known mediators of tumor invasiveness, and their induction implies that excessive CXCR4 blockade may not only fail to suppress metastatic potential in certain ovarian cancer subtypes but may actually enhance it. The study also noted changes in other metastatic and inflammatory markers, including ICAM-1, an intercellular adhesion molecule, and IL-6, an interleukin implicated in cancer cell invasiveness, underscoring the breadth of the compensatory network that cancer cells can mobilize under pharmacologic stress.

These findings carry profound implications for the design of CXCR4-targeted therapies in ovarian cancer. The study demonstrates that the biological response to CXCR4 inhibition is not a simple dose-response curve in which higher drug concentrations yield greater tumor suppression. Instead, the relationship is biphasic and highly dependent on the molecular lineage of the tumor. Moderate inhibition, represented by the 50 micromolar dose in this study, effectively suppressed oncogenic signaling pathways including Cyclin D1-driven proliferation and AKT-mediated survival. Excessive inhibition, however, triggered paradoxical compensatory responses that varied across ovarian cancer subtypes, with ES2 cells relying on a HIF1α-dependent adaptive stress mechanism and HAY cells engaging a HIF1α-independent pathway involving AKT rebound and metastatic enzyme upregulation.

The concept of adaptive stress signaling in targeted cancer therapy resistance is not new, but this study provides crucial mechanistic insight into how it operates specifically in the context of CXCR4 blockade in ovarian cancer. Prior research has established that cancer cells can activate compensatory survival networks when a primary oncogenic driver is inhibited, a phenomenon that has been documented across multiple targeted therapies. The present work extends this understanding by showing that the specific escape route chosen by the cancer cell is determined by its molecular subtype, meaning that a single therapeutic strategy may succeed in one ovarian cancer subtype while inadvertently promoting resistance in another.

The researchers conclude that therapeutic dose optimization is of critical importance when targeting the CXCL12/CXCR4 axis in ovarian cancer. Their data suggest that the limitations of high-dose CXCR4-targeted therapy are not merely a matter of toxicity but reflect a fundamental biological reality in which excessive pharmacologic pressure activates stress-induced adaptive programs that can restore oncogenic signaling and even enhance metastatic potential. As clinical trials of CXCR4 antagonists continue to advance across multiple cancer types, this study serves as a timely reminder that the dose at which these agents are deployed may be as important as the target itself, and that subtype-specific molecular profiling will be essential to predict which patients are most likely to benefit from this emerging class of therapeutics.

Subject of Research: Dose-dependent CXCR4 inhibition in ovarian cancer cellular models reveals a paradoxical response characterized by subtype-specific oncogenic suppression and stress-induced adaptive rebound

Article Title: Dose-dependent CXCR4 inhibition in ovarian cancer cellular models reveals a paradoxical response characterized by subtype-specific oncogenic suppression and stress-induced adaptive rebound

Article References: Alzu’bi, A., Abu-El-Rub, E., Alomari, G., Ghawanmeh, Y., Almazari, R., Hmedat, A., & Al-Zoubi, R. M. (2026). Dose-dependent CXCR4 inhibition in ovarian cancer cellular models reveals a paradoxical response characterized by subtype-specific oncogenic suppression and stress-induced adaptive rebound. Molecular Biology Reports, 53(1), Article 1728. https://doi.org/10.1007/s11033-026-12917-1

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12917-1

Keywords: ovarian cancer, CXCR4, CXCL12, USL311, HIF1α, AKT signaling, drug resistance, targeted therapy, Dose-dependent, inhibition, ovarian, cancer

Long non-coding RNAs, or lncRNAs, are transcripts longer than 200 nucleotides that are not translated into proteins but instead regulate gene expression at multiple levels, including chromatin remodeling, transcription, and post-transcriptional processing. In recent years, lncRNAs have been implicated in nearly every stage of cancer progression, from uncontrolled proliferation to metastasis and resistance to chemotherapy. Yet for many of these molecules, the precise biological roles and molecular mechanisms remain poorly understood. RBMS3-AS3 was one such enigma, and the team set out to determine whether it plays a functional role in ovarian cancer pathogenesis.

The researchers began by analyzing expression data from The Cancer Genome Atlas and from human ovarian cancer samples collected with informed consent under ethics approval from China Medical University. They found that RBMS3-AS3 is highly expressed in ovarian cancer tissues compared with normal ovarian tissue, and that elevated levels of the transcript correlate with poor overall survival in patients. This clinical association immediately suggested that RBMS3-AS3 is not merely a bystander but potentially an active participant in the disease process.

To understand where the molecule operates inside the cell, the team performed subcellular localization experiments and discovered that RBMS3-AS3 is predominantly cytoplasmic in ovarian cancer cells. This location is significant because the cytoplasm is where post-transcriptional regulation occurs, including mRNA stability, splicing, and protein interactions. A cytoplasmic lncRNA is therefore positioned to interact directly with RNA-binding proteins rather than to influence transcription at the DNA level.

Using small interfering RNAs to silence RBMS3-AS3 in ovarian cancer cell lines, the researchers observed a dramatic suppression of cell proliferation, migration, and invasive capacity. Conversely, when they overexpressed the transcript, these oncogenic behaviors were enhanced. The same pattern held true for the RNA-binding proteins QKI, also known as Quaking, and RBFOX2, or RNA binding fox-1 homolog 2. Silencing either protein individually suppressed the malignant phenotype, while overexpression promoted it, indicating that both proteins function as oncoproteins in this context.

Bioinformatic analyses, including gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment, identified QKI and RBFOX2 as potential downstream targets of RBMS3-AS3. To verify this experimentally, the team performed RNA pull-down assays and RNA immunoprecipitation, or RIP, experiments. These techniques confirmed a direct physical interaction between RBMS3-AS3 and both QKI and RBFOX2 proteins inside ovarian cancer cells. The binding was not indirect or coincidental but a genuine molecular handshake between the lncRNA transcript and the two RNA-binding proteins.

The most striking mechanistic discovery came when the researchers examined what happens to QKI and RBFOX2 protein levels in the absence of RBMS3-AS3. Using cycloheximide chase experiments to block new protein synthesis, they found that silencing RBMS3-AS3 accelerated the proteasomal degradation of both QKI and RBFOX2 proteins. The mechanism involved enhanced ubiquitination, the process by which ubiquitin molecules are attached to proteins to mark them for destruction by the proteasome. In other words, RBMS3-AS3 acts as a molecular bodyguard, physically binding to QKI and RBFOX2 and preventing their ubiquitination and subsequent degradation, thereby keeping the oncoproteins stable and active inside the cancer cell.

To confirm that QKI and RBFOX2 are the functional executors of RBMS3-AS3’s oncogenic effects, the team performed co-knockdown rescue experiments. When they simultaneously silenced both QKI and RBFOX2 in cells overexpressing RBMS3-AS3, the enhanced proliferation, migration, and invasion driven by the lncRNA were abolished. This rescue experiment demonstrates that the two RNA-binding proteins are not merely associated with RBMS3-AS3 but are required for its tumor-promoting function, establishing a clear causal chain from the lncRNA through the two oncoproteins to the malignant phenotype.

The study also carried out animal experiments following guidelines from the Institutional Animal Care and Use Committee of China Medical University, providing in vivo evidence that supports the cell-based findings. Together, the clinical correlation, the cytoplasmic localization, the direct binding assays, the ubiquitination mechanism, and the rescue experiments form a coherent and technically rigorous argument that RBMS3-AS3 promotes ovarian cancer malignant progression by physically binding to and stabilizing the oncoproteins QKI and RBFOX2.

The implications for ovarian cancer therapy are significant. Ovarian cancer is often diagnosed at an advanced stage and develops resistance to platinum-based chemotherapy, leaving patients with limited options. A therapeutic strategy that targets RBMS3-AS3, either through antisense oligonucleotides or small interfering RNA delivery, could destabilize QKI and RBFOX2 simultaneously and thereby undermine multiple oncogenic pathways at once. Because the mechanism is specific to the physical interaction between the lncRNA and the two proteins, it offers a precise molecular point of intervention. The authors conclude that RBMS3-AS3 may represent a promising novel therapeutic target for ovarian cancer intervention, and their findings open a new avenue for the development of lncRNA-directed therapies against this devastating disease.

Subject of Research: LncRNA RBMS3-AS3 promotes ovarian cancer progression by regulating QKI and RBFOX2

Article Title: LncRNA RBMS3-AS3 promotes ovarian cancer progression by regulating QKI and RBFOX2

Article References: Wu, Y., Zhao, H., Du, J., Tan, B., Zhang, Z., Wei, X., Xue, R., Zhang, J., Zhang, X., Jin, X., Tang, S., & Meng, X. (2026). LncRNA RBMS3-AS3 promotes ovarian cancer progression by regulating QKI and RBFOX2. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02303-7

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02303-7

Keywords: RBMS3-AS3, lncRNA, ovarian cancer, QKI, RBFOX2, RNA-binding proteins, ubiquitination, cancer therapy, promotes, ovarian, cancer, progression

Anti-mullerian hormone is produced by the granulosa cells of small growing follicles, and its serum level correlates with the number of follicles recruited into the growth phase at any given time. Because it remains relatively stable across the menstrual cycle, it can be measured on any day, although the study protocol here drew samples on days two through five to allow simultaneous measurement of follicle stimulating hormone and estradiol, which do fluctuate cyclically. Follicle stimulating hormone rises as the reserve declines, because the pituitary must work harder to recruit follicles when inhibin and estradiol feedback from the ovaries weakens, but by the time FSH becomes clearly elevated the reserve is often already substantially depleted, making it a relatively late and less sensitive marker. Antral follicular count, performed by transvaginal ultrasonography during the early follicular phase, counts the small follicles between roughly two and ten millimeters in diameter that are visible on both ovaries, and it generally correlates well with AMH because both reflect the same pool of growing follicles. Ovarian volume, the third ultrasonographic parameter used in a subset of patients, is a coarser measure that shrinks as the cortex is depleted of follicles, but it is less precise and more operator dependent.

The finding that nearly half of the studied cohort had AMH below one nanogram per milliliter, and that roughly two thirds fell below the tenth centile of age-matched healthy fertile women on nomogram comparison, is striking given the young mean age of twenty-seven years. Nomogram comparison is an important methodological choice here, because AMH declines with age in all women, and simply reporting mean values would obscure whether lupus patients are tracking below the curve expected for their age. By anchoring the comparison to population-specific centiles derived from healthy fertile women, the investigators could quantify how many patients were shifted toward the low end of the distribution beyond what age alone would explain. The use of Indian reference nomograms also matters, since preliminary evidence suggests that ovarian ageing may proceed somewhat faster in healthy Indian women than in populations from which many older reference ranges were derived, which would make the observed deficits even more notable if the lupus patients fell below even these local benchmarks.

The independent associations uncovered by the multivariable regression offer several threads for interpretation. The association with higher age is expected and mirrors the physiology of ovarian ageing, with each additional year carrying a modest but measurable increase in the odds of low AMH. The association with active disease is more intriguing, because it suggests that inflammatory activity itself, rather than merely the passage of time or the scars of past treatment, may be eroding the follicular pool. Several mechanisms could plausibly underlie such an effect. Systemic inflammation in lupus involves circulating cytokines such as interleukin-6 and tumor necrosis factor alpha, which can disrupt the hypothalamic-pituitary-ovarian axis and impair follicular development. Autoantibodies, immune complex deposition, and microvascular injury could compromise the blood supply to the ovary, and the ovary is notably vulnerable to ischemic damage because its follicular complement cannot regenerate. Oxidative stress generated by chronic inflammation may also accelerate apoptosis of oocytes and granulosa cells. The cross-sectional design of the study cannot distinguish whether active disease caused the low reserve or whether both reflect a shared underlying susceptibility, but the association is biologically coherent and aligns with observations in other inflammatory conditions where disease activity correlates with diminished reserve.

The link with menstrual irregularities, which more than quadrupled the odds of low AMH, is easier to interpret in one direction at least, since anovulation and oligomenorrhea frequently accompany a declining follicular pool. However, the relationship may also run partly in reverse, because lupus itself, thyroid dysfunction, hyperprolactinemia, stress, and weight changes can all disrupt cyclicity independently of reserve, meaning that menstrual irregularity is an imperfect proxy. Its strong statistical association with low AMH nonetheless suggests that clinicians seeing lupus patients with new cycle disturbances should consider ovarian reserve assessment rather than attributing the change solely to disease flares or medication effects.

The signal for anti-Ro60 positivity, which narrowly missed conventional statistical significance with a confidence interval crossing unity, is worth considering despite its borderline status. Anti-Ro antibodies are classically associated with neonatal lupus and congenital heart block, but they have also been implicated in adult autoimmune epithelial dysfunction, most notably in Sjogren syndrome and in the lymphocytic infiltration of salivary and lacrimal glands. Some investigators have proposed that similar lymphocytic infiltration of the ovary, sometimes described in the context of premature ovarian insufficiency, could be driven by the same antibody specificities, providing a plausible autoimmune route to follicular depletion that is independent of any gonadotoxic treatment. The modest effect size and borderline p value mean this finding requires confirmation in larger cohorts, but its biological plausibility and consistency with the broader concept of autoimmune premature ovarian failure make it a hypothesis worth pursuing.

Equally informative are the associations that failed to materialize. The absence of a relationship with prior cyclophosphamide exposure may seem surprising given the established gonadotoxicity of that agent, but several explanations are possible. The cumulative doses received by patients in this cohort may have been relatively low or administered with gonadoprotective measures, the most susceptible patients may have already been excluded through the low AMH screening threshold used in the parent trial, or the cross-sectional design may have selected for survivors whose reserve was already depleted regardless of treatment history. The lack of association with nephritis, anti-dsDNA, anti-Sm, and antiphospholipid antibodies suggests that organ damage patterns and specific autoantibody profiles other than anti-Ro are not the primary drivers of reserve loss, which redirects attention toward disease activity as the modifiable factor of interest.

The very low observed prevalence of premature ovarian insufficiency and early menopause, at under two percent each, coexists somewhat paradoxically with the high proportion of subnormal AMH values. This apparent tension resolves when one appreciates that premature ovarian insufficiency is a clinical diagnosis requiring amenorrhea and consistently elevated gonadotropins before the age of forty, representing the extreme tail of a distribution, whereas low AMH identifies women whose reserve is shifted downward long before they reach that threshold. Many women with low AMH will never develop premature menopause, and the interval between a low reserve measurement and actual menopause can span years to decades. The clinical implication is that low AMH in a young lupus patient should prompt counseling about reproductive timelines and consideration of fertility preservation options, but it should not be presented as a prediction of imminent sterility, which the evidence does not support and which can cause unnecessary distress.

For patients and clinicians, the practical takeaways are several. First, ovarian reserve assessment with AMH, and where available antral follicular count, is a reasonable component of comprehensive reproductive counseling for women with lupus, particularly those approaching their thirties, those with persistently active disease, and those with menstrual disturbances. Second, the finding that active disease independently predicts diminished reserve adds a reproductive dimension to the already compelling case for early and sustained disease control, since suppressing inflammation may protect not only organs but also the follicular pool. Third, the absence of an association with cyclophosphamide in this cohort should not be generalized to dismiss gonadotoxic risk, which is well established at higher cumulative doses, but it does suggest that reserve loss in lupus is not solely a treatment artifact. Fourth, women with low reserve who wish to delay childbearing should be informed about oocyte cryopreservation and other fertility preservation strategies, ideally before reserve declines further, and assisted reproductive technologies can be planned with realistic expectations when the time comes. Finally, the ethno-geographic dimension highlighted by this study underscores the need for population-specific reference ranges and for research across diverse cohorts, since findings from European and North American populations may not translate directly to South Asian patients, and the burden of lupus in India makes locally relevant evidence especially valuable for guiding care.

Subject of Research: Ovarian reserve in reproductive age Indian women with lupus

Article Title: Assessment of ovarian reserve in reproductive age Indian women with lupus and determination of correlates of diminished reserve: results from a tertiary care centre

Article References: Jain, S., Kumar, A., Verma, U. S., Gupta, S., Bharti, J., Gupta, R., Goswami, R. P., Bhadu, D., Soneja, M., Sinha, S., Kumar, U., & Wig, N. (2026). Assessment of ovarian reserve in reproductive age Indian women with lupus and determination of correlates of diminished reserve: results from a tertiary care centre. Frontiers in Lupus, 4, Article 1783078. https://doi.org/10.3389/flupu.2026.1783078

Image Credits: AI Generated

DOI: 10.3389/flupu.2026.1783078

Keywords: lupus, SLE, ovarian reserve, AMH, fertility, autoimmunity, Assessment, ovarian, reserve, reproductive, Indian, women

The study, published in Frontiers in Artificial Intelligence by Miruna-Cristina Andone, Loretta Ichim, and Dan Popescu of the National University of Science and Technology Politehnica of Bucharest, introduces a two-stage neural network fusion system. Rather than relying on a single deep learning model, the approach combines the strengths of several architectures in a layered ensemble, achieving an average F1 score of 93.53 percent across five classes, with recall of 93.38 percent and precision of 93.68 percent on an independent test cohort. Those numbers outperformed every individual network and every first-stage ensemble tested in the study.

The stakes are enormous. According to data cited in the paper, roughly 324,603 women were diagnosed with ovarian cancer in 2022, and the World Ovarian Cancer Coalition projects that four million lives will be lost to the disease by 2040, with approximately 12 million new cases diagnosed by 2050. Epithelial ovarian cancer accounts for about 95 percent of ovarian malignancies, and the five-year survival rate for late-stage diagnoses remains below 30 percent. Because the disease is often detected only after it has metastasized, when surgery may no longer be possible, earlier and more accurate imaging-based detection is a global health priority.

Traditional diagnosis and staging rely on manual analysis of CT and MRI scans, a process that is subjective, expensive, and prone to human error. Deep learning has begun to change that calculus. Neural networks can highlight tumor structures of various sizes, including small lesions that might escape a tired eye, and radiomic analysis can extract quantitative features that extend beyond what a radiologist sees. But individual models have weaknesses — they can be brittle, sensitive to noise, and inconsistent across varied data. Ensembles, which combine multiple models, offer a way to compensate for those deficiencies.

The Romanian team tested nine well-known architectures on the TCGA-OV dataset, a public collection from The Cancer Imaging Archive comprising 143 patients and 26,570 CT images. The architectures included U-Net, Attention U-Net, SegNet, ResNet50, VGG16, GoogLeNet, DenseNet-121, DeepLabV3+, and the Vision Transformer (ViT). Each was adapted for pixel-wise semantic segmentation, with classification-oriented networks stripped of their classification heads and fitted with segmentation decoders. The researchers then ranked the models using F1 score, recall, and precision for each of five classes, and selected the top three performers: Attention U-Net, DeepLabV3+, and ViT.

Those three networks bring complementary skills. Attention U-Net, a variant of the classic U-shaped encoder-decoder, uses attention mechanisms to focus on relevant regions of the image, sharpening its sensitivity to tumor edges and abnormal structures. DeepLabV3+ combines atrous — or dilated — convolutions with an effective decoder to capture contextual information at multiple spatial scales, excelling at boundary delineation. ViT, the newcomer among them, treats images as sequences of patches and uses self-attention to learn global relationships between distant regions, a capability that convolutional networks lack. Together, they cover local detail, contextual scale, and long-range coherence.

The first stage of fusion builds four ensembles from these three networks. Ensemble E1 uses binary voting, where each network casts a simple yes-or-no decision for each class. Ensembles E2, E3, and E4 use weighted scores based on F1, recall, and precision respectively, with weights assigned per network and per class. The second stage then fuses the outputs of all four ensembles into a Global System, weighted by the F1 scores of the first-level ensembles. At every step, the final classification of a pixel is determined by the highest weighted score across the five classes: No Tumor, Differentiated, Proliferative, Mesenchymal, and Immunoreactive.

One important nuance deserves attention. The four tumor classes beyond No Tumor are not read directly from the CT image. Instead, they are patient-level molecular subtype labels from The Cancer Genome Atlas genomic classifications, mapped onto the anatomically annotated tumor masks. The authors are explicit that this five-class formulation should not be interpreted as voxel-level prediction of molecular subtypes from imaging alone. Rather, the framework evaluates how accurately the models reproduce these mapped labels within segmented tumor regions, combining anatomical segmentation with subtype-derived labeling for multi-class analysis.

The experimental results show a clear progression. The three selected individual networks achieved average F1 scores between 86.01 and 86.59 percent on the test set. The first-level ensembles pushed that range to between 90.40 and 90.50 percent. The Global System then reached 93.53 percent. Patient-level analysis, which treats each subject as a single unit to account for the correlation among slices from the same patient, confirmed the pattern: the Global System achieved a mean patient-level F1 score of 93.5 ± 2.4 percent, compared with 91.8 percent for Attention U-Net, 91.5 percent for DeepLabV3+, and 92.1 percent for ViT. Paired Wilcoxon signed-rank tests showed the differences were statistically significant, with p-values ranging from 0.008 to 0.021.

The authors are careful about limitations. The testing cohort contains a limited number of independent subjects, and the same validation cohort was used both to select the component networks and to derive ensemble weights, which may introduce optimization bias. The study is a retrospective methodological evaluation on a public dataset, not a clinical validation. Boundary-based metrics such as Hausdorff distance were outside the predefined protocol. Still, the two-stage fusion framework demonstrates technical feasibility and points toward a future where multimodal integration — combining imaging with histopathology and genomic data — could sharpen diagnostic accuracy further. For a disease that claims roughly 150,000 lives annually, every percentage point of precision matters.

Subject of Research: Two-stage neural network fusion for ovarian cancer tumor segmentation from CT images

Article Title: Segmentation of ovarian cancer tumors from CT images based on a two-stage neural network fusion system

Article References: Andone, M.-C., Ichim, L., & Popescu, D. (2026). Segmentation of ovarian cancer tumors from CT images based on a two-stage neural network fusion system. Frontiers in Artificial Intelligence, 9, Article 1974931. https://doi.org/10.3389/frai.2026.1974931

Image Credits: AI Generated

DOI: 10.3389/frai.2026.1974931

Keywords: ovarian cancer, artificial intelligence, medical imaging, CT segmentation, neural networks, deep learning, ensemble models, TCGA-OV, Segmentation, ovarian, cancer, tumors

The team built its case on single-cell transcriptomics. Using both single-cell and single-nucleus RNA sequencing, the researchers generated a high-resolution cellular map of the mouse and human mediobasal hypothalamus, then integrated the two datasets computationally in a shared latent space to compare tanycytes across species. The integration workflow, based on deep generative models and probabilistic label transfer, allowed them to annotate eight tanycyte subclusters in the human tissue that correspond to subclusters defined in the mouse. Among these, one subcluster stood out. In both species, the T8 tanycyte state was enriched for genes associated with innate immunity, showing robust activation of interferon-α and interferon-γ response pathways and expression of downstream interferon-stimulated genes. In other words, a cell type conventionally classified as glia carries a transcriptional programme that resembles an immune cell state, and this programme is conserved between mouse and human hypothalamus.

What makes the finding striking is its dynamics. In female mice, the abundance and activity of this immune-associated tanycyte state changed across the oestrous cycle. The researchers captured sex-, oestrous cycle- and high-fat diet-dependent transcriptomic shifts in tanycytes, and found a cyclic expression of the gene encoding interferon regulatory factor 7 (Irf7), a master transcription factor of the interferon signalling family, together with downstream interferon-stimulated genes such as Cxcl10, a chemokine that recruits leukocytes. Spatial validation by RNAscope fluorescent in situ hybridization showed that Irf7 mRNA transcripts concentrated in defined ventricular regions of the arcuate nucleus and median eminence, and that regions containing CD45-high infiltrating leukocytes spatially coincided with zones of elevated Irf7 and Cxcl10 expression. In physiological males, by contrast, Irf7 expression in tanycytes remained stable and markedly lower, suggesting that cycling females mount a distinct pattern of immune activation in the brain that is tied to the changing hormonal milieu of the cycle, particularly oestradiol.

The mechanistic thread connecting oestradiol to interferon signalling runs through kinases. Upstream kinase analysis of oestradiol-regulated phosphosites in tanycytes identified TBK1 and IKKε, the canonical kinases that phosphorylate IRF7, as top hits with negative kinase statistics and high specificity scores, indicating that oestradiol treatment suppresses the activity of these IRF7-activating kinases. At the same time, imaging of NF-κB reporter mice revealed that κ-EGFP-positive tanycytes in the arcuate nucleus and median eminence increased at oestrus compared with diestrus, and that vimentin-stained tanycyte processes contacted κ-EGFP-positive microglia and CD45-positive immune cell complexes near vessels. Oestradiol thus appears to engage both the NF-κB and interferon regulatory signalling axes in tanycytes and in the immune cells of the median eminence, positioning these glial cells as integrators of endocrine and inflammatory signals at the brain’s metabolic gateway.

To test whether this cyclic immune programme matters functionally, the team manipulated oestrogen and interferon signalling in tanycytes. Ovariectomy with and without oestradiol replacement altered serum oestradiol levels and changed tanycytic IRF7 activity and leukocyte infiltration into the median eminence. The data support a model in which balanced, cyclic leukocyte infiltration into the median eminence may have a role in maintaining the oestrous cycle itself. This is a provocative idea: rather than viewing immune cell traffic across the permeable median eminence as pathological inflammation, the study suggests that a controlled, hormone-gated influx of leukocytes could be part of the physiological machinery that supports reproductive cycling, with tanycytes orchestrating the timing through interferon-dependent chemokine release.

The reach of tanycytic IRF7 extends beyond the brain. By selectively depleting Irf7 in tanycytes using an adeno-associated viral vector carrying an Irf7 short hairpin RNA, delivered into the lateral ventricle with a Dio2 promoter-driven Cre recombinase that restricts recombination to tanycytes, the researchers generated mice with tanycyte-specific Irf7 knockdown. RNAscope quantification confirmed the reduction of Irf7 mRNA transcripts in the knockdown animals. Flow cytometry of circulating blood then revealed that Irf7 in tanycytes modulates the proportions of circulating monocytes, the classical, intermediate and non-classical subsets that patrol vessels and migrate into tissues. Neutrophils, eosinophils, natural killer cells and T cell populations were unchanged, indicating a selective effect on the monocyte compartment. The finding provides direct evidence of brain-to-immune system communication through tanycytes, echoing earlier work showing that hypothalamic sensing of metabolic state regulates circulating monocytes.

How could glial cells lining a brain ventricle influence the blood immune compartment? The most plausible route lies in the anatomy of the median eminence, where tanycytes form the blood–hypothalamus barrier and contact both the portal vasculature and the cerebrospinal fluid. Tanycytes release chemokines such as CXCL10 in an interferon-dependent manner, and their processes extend toward vessels and immune cell complexes in the arcuate nucleus. Signalling through this interface could alter the cytokine milieu that reaching monocytes encounter, or modify endothelial and perivascular cues that determine monocyte egress from the bone marrow and patrolling behaviour in the bloodstream. The study also documented cyclic cytokine responses, with serum concentrations of inflammatory cytokines measured across the oestrous cycle, and found that interferon-γ pathway components, including Ifng, Tbx21 and the interferon-γ receptor subunits, were expressed in the mediobasal hypothalamus, providing potential ligand–receptor pairs that could drive the tanycytic interferon programme during the cycle.

The cross-species dimension of the work strengthens its relevance to human biology. Human tanycyte subclusters predicted by the computational integration showed the same enrichment of interferon-α and interferon-γ response pathways and interferon-stimulated gene expression in the human T8 state as in the mouse. The human samples came from single-nucleus sequencing of the mediobasal hypothalamus of donors, including donors with Alzheimer’s disease, frontotemporal dementia, type 2 diabetes and chronic myelomonocytic leukemia, and the descriptive analyses showed that the immune-associated tanycyte state was present across sexes and pathological conditions. Because sex-biased differences in metabolic and immune function are shaped by endocrine–immune interactions, the identification of a conserved, hormone-responsive immune programme in tanycytes offers a cellular substrate for understanding why many inflammatory, metabolic and neurodegenerative diseases show sex-biased incidence and progression.

Technically, the study exemplifies the current generation of single-cell neuroscience. The researchers used scVI-based deep generative modelling to integrate mouse and human datasets, scANVI for probabilistic label transfer of tanycyte subclusters, SCENIC for transcription factor regulon inference that identified the Irf7 regulon and its two target subnetworks enriched for innate immune and interferon-related functions and for antigen presentation and leukocyte activation, and scProportionTest with permutation-based cell-level statistics to quantify changes in subcluster abundance between conditions. Spatial transcriptomic validation with published hypothalamic atlases and RNAscope in situ hybridization anchored the cell states to defined anatomical zones along the anteroposterior axis of the third ventricle. Kinome assays with serine–threonine phosphosite analysis connected oestradiol to the IRF7 phosphorylating kinases. The combination of computational and spatial methods, together with physiological follow-up of body weight, fat mass and blood glucose in the sequenced animals, gives the findings a solid technical footing.

The implications reach toward several frontiers. If cyclic interferon signalling in tanycytes gates leukocyte traffic into the median eminence and shapes circulating monocyte proportions, then disruptions of this programme, whether by chronic high-fat diet, by loss of ovarian hormones, or by pathological inflammation, could alter both reproductive function and systemic immune regulation. The study’s observation that high-fat diet feeding changed tanycytic transcriptomic states, and that the immune-associated state responded to diet and cycle in combination, suggests that metabolic disease may reprogramme the brain’s immune interface. Conversely, the tanycyte degeneration linked to impaired tau clearance in recent work hints that these cells also participate in neurodegenerative pathology. By revealing an immune-associated role for tanycytes and a conserved, oestradiol-responsive IRF7 programme that communicates between brain, body and immune system across the ovarian cycle, the study opens a new chapter in neuroendocrine immunology, one in which the glial border of the metabolic brain is not merely a barrier but an active, hormone-gated immune organ.

Subject of Research: IRF7 signalling in tanycytes controls brain–body–immune response across the ovarian cycle

Article Title: IRF7 signalling in tanycytes controls brain–body–immune response across the ovarian cycle

Article References: Nampoothiri, S., Fernandois, D., Journiac, N., Delahaye, F., Mbouamboua, Y., Sauve, F., Couralet, M., Gallet, S., Mroueh, N., Serradas Aponte, M. L., Jouy, N., Spenle, R., Schmidt-Ullrich, R., Corral, I. M., Mattot, V., Almodovar, C. R. D., Schlitzer, A., Froguel, P., Maurage, C.-A., … Prevot, V. (2026). IRF7 signalling in tanycytes controls brain–body–immune response across the ovarian cycle. Nature Metabolism. https://doi.org/10.1038/s42255-026-01635-4

Image Credits: AI Generated

DOI: 10.1038/s42255-026-01635-4

Keywords: IRF7, signalling, tanycytes, controls, brain, body, immune, response, across, ovarian, cycle, scientific research

The review’s neuroendocrine story begins with the hypothalamic–pituitary–adrenal axis, the body’s master stress circuit. When psychological stress persists, the hypothalamus releases corticotropin-releasing hormone, which prompts the pituitary to secrete adrenocorticotropic hormone and finally drives the adrenal cortex to flood the bloodstream with cortisol. In short bursts this response is protective, but sustained cortisol elevation suppresses the pulsatile release of gonadotropin-releasing hormone from the hypothalamus. That pulsatility is the metronome of the reproductive system: when it falters, the pituitary secretes less luteinising hormone and follicle-stimulating hormone, the two signals that orchestrate follicle maturation and ovulation. The result is a disrupted hypothalamic–pituitary–gonadal axis, impaired folliculogenesis, irregular or absent ovulation, and menstrual cycles that drift from oligomenorrhea to amenorrhea.

Clinical evidence supports this mechanism. A study by Schliep and colleagues found that women with higher perceived stress showed altered ovulatory patterns across their cycles, while Lawson and colleagues demonstrated that hypercortisolemia directly impairs reproductive hormone secretion. The review also cites epidemiological work by Louis and colleagues showing that stress reduces conception probabilities across the fertile window. Stress, in other words, is not merely a feeling that accompanies infertility—it may be an active physiological participant in it.

The ovaries themselves bear a direct cellular burden from chronic stress. The review describes how sustained stress exposure generates oxidative stress, mitochondrial dysfunction, and apoptosis in ovarian cells, damaging oocyte competence and diminishing ovarian reserve. Animal studies cited in the review show that chronic restraint stress induces excessive activation of primordial follicles in mouse ovaries, causing the finite pool of eggs to deplete faster than it should. Gao and colleagues reported that stress reduces ovarian reserve, while Jiang and colleagues linked chronic stress to accelerated ovarian ageing and hindered folliculogenesis. Because oocyte quality is the primary determinant of success in assisted reproductive technologies, these cellular effects ripple outward into real-world fertility outcomes, including reduced fertilisation success and poorer embryo development.

But the review’s most provocative contribution is its emphasis on the gut. Psychological stress reshapes the composition of gut microbiota, reducing beneficial bacteria such as Lactobobacillus and Bifidobacterium while allowing opportunistic taxa like Clostridium to proliferate. This dysbiosis disrupts the estrobolome, the collection of microbial genes that metabolise oestrogen through deconjugation and recirculation. When the estrobolome falters, oestrogen levels shift in ways that affect ovulation, menstrual regulation, and endometrial function. The gut, in this framework, is not just a digestive organ but an endocrine co-processor that helps determine how much oestrogen actually circulates in a woman’s blood.

Dysbiosis also weakens the intestinal barrier. Reduced production of short-chain fatty acids—particularly butyrate, acetate, and propionate—compromises the gut lining, allowing bacterial lipopolysaccharide and other microbial molecules to leak into the bloodstream. This permeability triggers systemic inflammation, evidenced by elevated interleukin-6, tumour necrosis factor-alpha, and C-reactive protein. The review argues that these inflammatory mediators adversely affect endometrial receptivity and implantation success, shifting the endometrium away from the immune-balanced state required during the implantation window. Chronic inflammation also promotes glucocorticoid resistance, in which immune cells become less responsive to cortisol’s anti-inflammatory signals, creating a self-perpetuating cycle of persistent immune activation and tissue damage in reproductive organs.

The review extends this framework to specific clinical conditions. In polycystic ovary syndrome, stress-related HPA-axis activation may interact with insulin resistance, hyperandrogenism, and obesity, while gut microbial alterations have been reported in PCOS patients, though their causal role remains uncertain. In endometriosis, chronic pain and infertility substantially increase anxiety and perceived stress, and stress-related immune changes may amplify pain and inflammation, though the relationship is described as bidirectional rather than causal. In infertility and assisted reproduction, the review is careful to note that evidence that psychological distress independently reduces IVF success remains inconsistent, and that psychological support should be offered to improve well-being and treatment engagement rather than being presented as a guaranteed method for increasing pregnancy rates.

Emerging evidence also implicates microbial metabolites in reproductive signalling. Short-chain fatty acids, tryptophan-derived metabolites, and serotonin produced by gut bacteria modulate neuroendocrine signalling and ovarian function. Cryan and colleagues demonstrated that microbial diversity is crucial for maintaining proper oestrogen levels in the bloodstream, and Clarke and colleagues showed that microbial imbalances produce behavioural changes and alter stress resilience, creating a feedback loop between psychological and physical health. The review also notes that the female reproductive tract harbours its own microbiota, with Lactobacillus-dominated communities in the vagina maintaining a protective low-pH environment, while the cervix, endometrium, fallopian tubes, and ovaries host smaller microbial biomass whose disruption has been linked to bacterial vaginosis, pelvic inflammatory disease, endometriosis, and implantation failure.

Despite the biological plausibility of these mechanisms, the review acknowledges significant translational gaps. Current approaches rely on discrete biomarkers such as cortisol, GnRH, IL-6, TNF-alpha, and C-reactive protein, but these are often studied in isolation, limiting diagnostic sensitivity and specificity. The predominance of observational and cross-sectional study designs makes causal inference difficult, and microbiome research in this domain remains largely correlative. The authors call for longitudinal, multi-omics methodologies integrating genomics, metabolomics, and microbiomics to achieve a systems-level understanding of the gut–brain–ovary axis, alongside well-designed randomised controlled trials with standardised protocols.

Therapeutically, the review advocates an integrative approach. Cognitive behavioural therapy, mindfulness, relaxation training, and counselling can decrease anxiety and enhance emotional resilience, potentially restoring HPA–HPG axis communication. Lifestyle modifications—good nutrition, physical activity, proper sleep, and maintaining a healthy weight—support metabolic, microbial, and hormonal processes. Microbiome-targeted interventions, including probiotics, prebiotics, and dietary strategies, are promising but require further clinical validation before becoming standard treatment options. The authors conclude that psychological well-being should be considered an integral part of reproductive health, but that microbiome-modifying interventions should not be implemented hastily before being validated. The mind–body connection in women’s reproductive health, they argue, is not a metaphor but a measurable biological network—and understanding it may ultimately improve both fertility and overall well-being.

Subject of Research: The mind–body connection in women’s reproductive health: how psychological stress shapes gut and ovarian function – a narrative review

Article Title: The mind–body connection in women’s reproductive health: how psychological stress shapes gut and ovarian function – a narrative review

Article References: Yachanahalli Purushotham, A., Shilpa, B. M., & Sundaram, D. (2026). The mind–body connection in women’s reproductive health: how psychological stress shapes gut and ovarian function – a narrative review. Frontiers in Gastroenterology, 5, Article 1854862. https://doi.org/10.3389/fgstr.2026.1854862

Image Credits: AI Generated

DOI: 10.3389/fgstr.2026.1854862

Keywords: mind, body, connection, women, reproductive, health, psychological, stress, shapes, ovarian, function, narrative

The formula is an eleven-herb decoction whose largest components are processed Rehmanniae radix praeparata and Atractylodes macrocephala, each weighing 30 grams in the standard prescription, followed by Rhizoma dioscoreae and Angelicae sinensis radix at 15 grams apiece. Smaller quantities of Paeoniae radix alba, Ziziphi spinosae semen, Glehniae radix, Moutan cortex, Eucommiae cortex, Radix bupleuri and Panax ginseng complete the prescription. Clinically, the decoction is used to tonify the kidney, regulate liver function, nourish blood and normalize menstruation. Earlier clinical work indicated that the formula increases the number of antral follicles, retrieved oocytes, mature oocytes and high-quality embryos, thereby improving in vitro fertilization outcomes in older patients. Network pharmacology analyses had pointed toward oxidative stress and angiogenesis as likely targets, but the precise molecular mechanism remained unresolved.

To test the formula systematically, the researchers established a diminished ovarian reserve model in female ICR mice using a single intraperitoneal injection of cyclophosphamide, a chemotherapy drug that depletes the ovarian follicle pool. Seventy-two mice with regular estrous cycles were divided into six groups: an untreated control, a disease model group, three Yijing Decoction dose groups receiving 0.9, 1.8 or 3.6 grams per kilogram by oral gavage, and a comparison group receiving estradiol valerate. Treatment continued for eight weeks. The team then evaluated ovarian index, estrous cycle regularity, serum levels of follicle-stimulating hormone, luteinizing hormone, estradiol, anti-Müllerian hormone and inhibin B, and histological follicle counts across all developmental stages.

The results showed a coherent pattern of restoration. Mice in the model group lost body weight, showed a profound reduction in ovarian index and developed persistent estrous cycle irregularities dominated by prolonged inter-estrous intervals. Serum follicle-stimulating hormone and luteinizing hormone surged, while estradiol, anti-Müllerian hormone and inhibin B plummeted. Histology revealed significant losses of primordial, primary and mature follicles alongside elevated numbers of atretic follicles and corpora lutea. High-dose Yijing Decoction reversed most of these changes: primordial and mature follicle counts recovered, atretic follicles declined, anti-Müllerian hormone and inhibin B rose, and estrous cyclicity normalized. The estradiol valerate comparison group produced broadly similar improvements, providing a pharmacological benchmark for the herbal intervention.

The most striking findings concerned the oocytes themselves. At the metaphase I stage, oocytes from diseased mice were fewer in number, morphologically aberrant and increasingly fragmented. Their meiotic spindles, the barrel-shaped microtubule structures that orchestrate chromosome segregation, were severely disorganized. Spindle assembly is extraordinarily energy-dependent, and consistent with this, intracellular ATP levels in the diseased oocytes were dramatically lower than in controls. After treatment with medium-dose or high-dose Yijing Decoction, the majority of oocytes regained a typical bipolar barrel-shaped spindle, and ATP levels were significantly restored. High-dose treatment also significantly increased the number of ovulated oocytes.

To explain this bioenergetic rescue, the researchers turned to glycolysis, the metabolic pathway that converts glucose and pyruvate into modest amounts of ATP and, ultimately, lactate. During normal oocyte maturation, glycolysis is transcriptionally suppressed because its ATP yield per mole of substrate is low; instead, mitochondrial oxidative phosphorylation dominates energy production. Immunofluorescence microscopy revealed that oocytes from diseased mice expressed abnormally high levels of the glucose transporters GLUT1 and GLUT4 and of lactate dehydrogenase A, the enzyme that converts pyruvate to lactate. Pyruvate uptake and lactate production, quantified using fluorescence-based assay kits in 150 to 200 oocytes per group, were both significantly elevated, indicating hyperactive glycolytic flux. Yijing Decoction treatment downregulated the glycolytic proteins, reduced pyruvate uptake and decreased lactate production, effectively steering metabolism back toward mitochondrial ATP generation.

The mechanistic thread connecting these observations is the SIRT3/HIF-1α/PDK1 signaling axis. SIRT3 is an NAD+-dependent mitochondrial deacetylase that negatively regulates glycolysis by promoting the degradation of hypoxia-inducible factor-1α, a master transcriptional activator of glycolytic genes. When SIRT3 falls, HIF-1α accumulates and drives expression of pyruvate dehydrogenase kinase 1, an enzyme that phosphorylates and inhibits the pyruvate dehydrogenase complex. This blocks the conversion of pyruvate to acetyl-CoA, diverts glycolytic flux toward lactate and starves the mitochondria of substrate. In the diseased oocytes, SIRT3 was significantly downregulated while HIF-1α and PDK1 were markedly upregulated. Yijing Decoction partially restored this expression pattern, upregulating SIRT3 while suppressing HIF-1α and PDK1.

Supporting evidence from independent studies reinforces the plausibility of this axis. Metabolomic analysis of human oocytes has shown that aging is accompanied by increased pyruvate and lactate levels and impaired mitochondrial metabolism, particularly at the metaphase I stage. Patients with diminished ovarian reserve exhibit disturbances in glucose metabolism and lactate-related pathways in ovarian granulosa cells. Experimental overexpression of SIRT3 has been shown to improve oocyte developmental competence, and SIRT3 mRNA levels are significantly lower in granulosa cells from older pregnant women relative to younger women with normal ovarian reserve. Culture media engineered to maintain low lactate levels suppress reactive oxygen species accumulation and enhance metabolic efficiency in oocytes, and faster meiotic resumption correlates with lower glycolytic flux.

The authors acknowledge important limitations. Rescue experiments using SIRT3-knockout mice or pharmacological inhibitors of pathway components were not performed, so direct causal evidence linking the formula’s effects to the SIRT3/HIF-1α/PDK1 axis remains lacking. The scarcity of oocytes prevented validation by RT-qPCR and Western blot. Food consumption was not systematically quantified, leaving unclear whether body weight changes reflected altered intake. Functional endpoints such as polar body extrusion and fertilization rates were not assessed, and the study evaluated the decoction as an integral multi-component formula rather than identifying individual bioactive constituents, although prior chemical characterization identified blood-absorbed compounds with reported ovarian-protective activities, including paeoniflorin, ginsenoside Rg1, naringin and hesperidin.

Nevertheless, the findings open a genuinely novel dimension in reproductive biology: the idea that a traditional herbal formula may protect the oocyte by correcting a metabolic imbalance rather than by simply supplementing hormones. If future work confirms that modulating lactate metabolism through the SIRT3/HIF-1α/PDK1 axis can improve oocyte quality in women with diminished ovarian reserve, the implications for fertility treatment could be substantial. The study provides new insights into the association between lactate metabolism-related mechanisms and the protective effects of Yijing Decoction, and the authors call for further investigation integrating rescue experiments, molecular validation and bioactivity-guided chemical study to establish the active chemical basis and confirm the therapeutic relevance of this ancient prescription in modern reproductive medicine.

Subject of Research: Yijing Decoction improves oocyte quality and inhibits lactate accumulation in mice with diminished ovarian reserve

Article Title: Yijing Decoction improves oocyte quality and inhibits lactate accumulation in mice with diminished ovarian reserve

Article References: Yang, J., Chu, M., Zhang, H., Meng, W., Zhang, C., Han, Y., Zeng, G., Zhou, Q., Zhang, X., Zhang, F., & Yan, Y. (2026). Yijing Decoction improves oocyte quality and inhibits lactate accumulation in mice with diminished ovarian reserve. Frontiers in Molecular Biosciences, 13, Article 1946851. https://doi.org/10.3389/fmolb.2026.1946851

Image Credits: AI Generated

DOI: 10.3389/fmolb.2026.1946851

Keywords: Yijing, Decoction, improves, oocyte, quality, inhibits, lactate, accumulation, mice, diminished, ovarian, reserve